Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial

BACKGROUND: Transmission blocking vaccines targeting the sexual-stages of the malaria parasite could play a major role to achieve elimination and eradication of malaria. The Plasmodium falciparum Pfs25 protein (Pfs25) is the most clinically advanced candidate sexual-stage antigen. IMX313, a compleme...

Descripción completa

Detalles Bibliográficos
Autores principales: de Graaf, Hans, Payne, Ruth O., Taylor, Iona, Miura, Kazutoyo, Long, Carol A., Elias, Sean C., Zaric, Marija, Minassian, Angela M., Silk, Sarah E., Li, Lee, Poulton, Ian D., Baker, Megan, Draper, Simon J., Gbesemete, Diane, Brendish, Nathan J., Martins, Filipa, Marini, Arianna, Mekhaiel, David, Edwards, Nick J., Roberts, Rachel, Vekemans, Johan, Moyle, Sarah, Faust, Saul N., Berrie, Eleanor, Lawrie, Alison M., Hill, Fergal, Hill, Adrian V. S., Biswas, Sumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318801/
https://www.ncbi.nlm.nih.gov/pubmed/34335606
http://dx.doi.org/10.3389/fimmu.2021.694759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318801/
https://www.ncbi.nlm.nih.gov/pubmed/34335606
http://dx.doi.org/10.3389/fimmu.2021.694759

Ejemplares similares